4.6 Article

Platelet dysfunction and thrombus instability in flow conditions in patients with severe COVID-19

Journal

THROMBOSIS RESEARCH
Volume 221, Issue -, Pages 137-148

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2022.11.004

Keywords

Platelets; COVID-19; Thrombosis; Bleeding; thrombus instability

Ask authors/readers for more resources

Severe COVID-19 is associated with both high rates of thrombotic and bleeding events. Platelet function in these events is uncertain, but this study found that platelets in severe COVID-19 patients showed pre-activation and exhaustion, reduced response to platelet agonists, and decreased adhesion to fibrinogen. The study also suggests that a plasma factor may contribute to the hyporesponsiveness of platelets. These findings highlight the need to carefully evaluate the risks and benefits of high-dose prophylactic anticoagulation in severe COVID-19 patients. Trial registration: ClinicalTrials.gov identifier: NCT04359992.
Severe COVID-19 has been associated with a high rate of thrombotic events but also of bleeding events, particularly when the level of prophylactic anticoagulation was increased. Data on the contribution of platelets to these thrombotic events are discordant between reports, while the involvement of platelets in bleeding events has never been investigated. The objective of the present study was to assess platelet function during the first week of ICU hospitalization in patients with severe COVID-19 pneumonia. A total of 35 patients were prospectively included and blood samples were drawn on day (D) 0, D2 and D7. COVID-19 pneumonia was severe with a median PaO2/FiO2 ratio of 91 [68-119] on D0. Platelets from these patients showed evidence of pre-activation and exhaustion with a significant reduction in the surface expression of GPVI, GPIb and GPIIbIIIa, together with a decrease in serotonin content. Platelets from patients with severe COVID-19 were hyporesponsive with a reduced maximal aggregation response to several platelet agonists and decreased adhesion to immobilized fibrinogen. Aggregation of washed platelets and plasma substitution experiments indicated that a plasma factor was at least partially responsible for this hyporeactivity of platelets. Blood flow experiments showed that severe COVID-19 platelets formed smaller, less stable aggregates on a collagen-coated surface, which could explain why some patients develop bleeding events. These findings should prompt us to carefully evaluate the risks and benefits of high-dose prophylactic anticoagulation, and to decrease the level of anticoagulation once the initial phase of the disease has resolved.Trial registration: ClinicalTrials.gov identifier: NCT04359992.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available